Brainstorm Cell Therapeutics BCLI Stock
Brainstorm Cell Therapeutics Price Chart
Brainstorm Cell Therapeutics BCLI Financial and Trading Overview
| Brainstorm Cell Therapeutics stock price | 1.56 USD |
| Previous Close | 2.72 USD |
| Open | 2.72 USD |
| Bid | 2.65 USD x 1400 |
| Ask | 2.81 USD x 800 |
| Day's Range | 2.68 - 2.82 USD |
| 52 Week Range | 1.09 - 4.7 USD |
| Volume | 155.22K USD |
| Avg. Volume | 394.37K USD |
| Market Cap | 106.8M USD |
| Beta (5Y Monthly) | -0.381773 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.45 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 15 USD |
BCLI Valuation Measures
| Enterprise Value | 112.98M USD |
| Trailing P/E | N/A |
| Forward P/E | -5.211539 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -4.665 |
Trading Information
Brainstorm Cell Therapeutics Stock Price History
| Beta (5Y Monthly) | -0.381773 |
| 52-Week Change | -1.44% |
| S&P500 52-Week Change | 19.24% |
| 52 Week High | 4.7 USD |
| 52 Week Low | 1.09 USD |
| 50-Day Moving Average | 2.87 USD |
| 200-Day Moving Average | 2.58 USD |
BCLI Share Statistics
| Avg. Volume (3 month) | 394.37K USD |
| Avg. Daily Volume (10-Days) | 222.34K USD |
| Shares Outstanding | 39.41M |
| Float | 32.73M |
| Short Ratio | 13.08 |
| % Held by Insiders | 24.00% |
| % Held by Institutions | 10.62% |
| Shares Short | 2.88M |
| Short % of Float | 7.82% |
| Short % of Shares Outstanding | 7.29% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:15 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -90.96% |
| Return on Equity (ttm) | -497.065% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -24220000 USD |
| Net Income Avi to Common (ttm) | -23976000 USD |
| Diluted EPS (ttm) | -0.63 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 2.23M USD |
| Total Cash Per Share (mrq) | 0.06 USD |
| Total Debt (mrq) | 3.68M USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 0.281 |
| Book Value Per Share (mrq) | -0.126 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -19618000 USD |
| Levered Free Cash Flow (ttm) | -10421250 USD |
Profile of Brainstorm Cell Therapeutics
| Country | United States |
| State | NY |
| City | New York |
| Address | 1325 Avenue of Americas |
| ZIP | 10019 |
| Phone | 201 488 0460 |
| Website | https://www.brainstorm-cell.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 41 |
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.
Q&A For Brainstorm Cell Therapeutics Stock
What is a current BCLI stock price?
Brainstorm Cell Therapeutics BCLI stock price today per share is 1.56 USD.
How to purchase Brainstorm Cell Therapeutics stock?
You can buy BCLI shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Brainstorm Cell Therapeutics?
The stock symbol or ticker of Brainstorm Cell Therapeutics is BCLI.
Which industry does the Brainstorm Cell Therapeutics company belong to?
The Brainstorm Cell Therapeutics industry is Biotechnology.
How many shares does Brainstorm Cell Therapeutics have in circulation?
The max supply of Brainstorm Cell Therapeutics shares is 5.7M.
What is Brainstorm Cell Therapeutics Price to Earnings Ratio (PE Ratio)?
Brainstorm Cell Therapeutics PE Ratio is now.
What was Brainstorm Cell Therapeutics earnings per share over the trailing 12 months (TTM)?
Brainstorm Cell Therapeutics EPS is -3.45 USD over the trailing 12 months.
Which sector does the Brainstorm Cell Therapeutics company belong to?
The Brainstorm Cell Therapeutics sector is Healthcare.
Brainstorm Cell Therapeutics BCLI included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 18350.19 USD — |
-2.64
|
7.23B USD — | 18216.63 USD — | 18992.3 USD — | — - | 7.23B USD — |
| NASDAQ Capital Market Composite RCMP | 102.02 USD — |
-3.29
|
— — | 101.66 USD — | 107.21 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 993.66 USD — |
-1.66
|
— — | 990.15 USD — | 1016.8 USD — | — - | — — |
| NASDAQ Composite Total Return I XCMP | 22440.37 USD — |
-2.64
|
— — | 22277.04 USD — | 23225.6 USD — | — - | — — |
- {{ link.label }} {{link}}